Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007)
Yara Abdou, Jess R. Hoag, William Eric Barlow, Kathy S. Albain et autres
BACKGROUND: The RxPONDER trial has guided adjuvant chemotherapy use in node-positive HR+/HER2- breast cancer; however, prior analyses showed poorer outcomes among non-Hispanic Black (NHB) women compared with non-Hispanic White (NHW) women despite similar 21-gene Recurrence Score® (RS) results. This suggests contributors to …
us, ca (code pays fourni par la source)